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Defining the mode(s) of action by which chemicals induce tu-
mors in laboratory animals has become a key to judgments about
the relevance of such tumor data for human risk assessment.
Frameworks for analyzing mode of action information appear in
recent U.S. EPA and IPCS publications relating to cancer risk
assessment. This FORUM paper emphasizes that mode of action
analytical frameworks depend on both qualitative and quantita-
tive evaluations of relevant data and information: (1) presenting
key events in the animal mode of action, (2) developing a “con-
cordance” table for side-by-side comparison of key events as de-
fined in animal studies with comparable information from human
systems, and (3) using data and information from mode of action
analyses, as well as information on relative sensitivity and expo-
sure, to make weight-of-evidence judgments about the relevance of
animal tumors for human cancer assessments. The paper features
a systematic analysis for using mode of action information from
animal and human studies, based in part on case examples involv-
ing environmental chemicals and pharmaceuticals.
Key Words: carcinogenic mode of action; human relevance of
animal tumors; risk assessment; PPAR agonists.
For several decades, potential carcinogenic hazard to hu-
mans has been identified primarily on the basis of long-term
animal bioassays. Relatively standardized protocols have been
established for studies in rodents, particularly rats and mice. As
in all experiments in animals, two fundamental assumptions
are made: (1) the results in the animal bioassay are relevant to
humans (interspecies extrapolation); and (2) the doses used in
the animal bioassay are relevant for estimating risk at known or
expected human exposure levels (dose extrapolation). Al-
though these assumptions are valid for many chemicals with
respect to carcinogenesis, progress during the past four decades
in our understanding of the mode of action of carcinogenesis
has greatly improved our ability to rigorously evaluate these
assumptions for specific chemicals. This is critical for a ratio-
nal assessment of hazard and risk to humans.
A fundamental breakthrough in our progress in understand-
ing mode of action was the distinction between DNA reactivity
and non-DNA reactivity, more broadly referred to as genotoxic
versus nongenotoxic modes of action. As progress has been
made in determining the modes of action of chemicals that
produce neoplasia in animal assays, it has become increasingly
important to evaluate the relevance of these modes of action
with respect to humans.
To address the issue of the human relevance of the mode(s)
of action determined in animals, a working group was formed
under the sponsorship of the U.S. Environmental Protection
Agency (EPA) and Health Canada, organized by the Interna-
tional Life Sciences Institute Risk Science Institute (ILSI RSI).
Based on the mode of action frameworks developed by the
International Programme on Chemical Safety (IPCS) (Sonich-
Mullin et al., 2001) and the U.S. EPA (U.S. EPA, 1999),
commonly used today by other regulatory agencies and inter-
national organizations (e.g., the World Health Organization,
Expert Panel of the Joint Meeting on Pesticide Residues), RSI
charged the working group with expanding these frameworks
to include evaluating the human relevance of modes of action
determined in animals. The details of the process, the case
studies, and the framework are published as a series of papers
in the November 2003 issue of Critical Reviews in Toxicology
(CRT) (Cohen et al., 2003; Meek et al., 2003). The present
article briefly describes the framework and provides a user’s
guide for its application. While brief references to specific
The views expressed in this report are those of the individual authors and not
necessarily those of the organizations they represent.
Preliminary versions of this work were presented at the Society for Risk
Analysis meeting in New Orleans in December 2002 and at the Society of
Toxicology Meeting in Salt Lake City in March 2003.
1 To whom correspondence should be addressed at University of Nebraska
Medical Center, Department of Pathology/Microbiology, 983135 Nebraska
Medical Center, Omaha, NE. Fax: (402) 559-9297. E-mail: scohen@unmc.edu.
Toxicological Sciences vol. 78 no. 2 © Society of Toxicology 2004; all rights
reserved.
TOXICOLOGICAL SCIENCES 78, 181–186 (2004)
DOI: 10.1093/toxsci/kfh073
Advance Access publication January 21, 2004
181
examples on which the framework is based are included, the
details are provided in the CRT papers mentioned above.
Several iterations of case studies of chemicals with generally
well-known modes of action were used to develop this frame-
work. The intent is to provide guidance for a disciplined,
transparent process evaluating the mode of action in animals
and each key event (see below) with respect to human rele-
vance.
The expanded human relevance framework is based on three
fundamental questions, followed by an explicit description of
confidence in the evaluation, identification of specific data
gaps, and the implications for risk assessment. It is emphasized
that this framework is intended to be used as part of the hazard
characterization step of the overall risk assessment process.
THE FRAMEWORK
The human relevance framework developed by the working
group is summarized as follows:
1. Is the weight of evidence sufficient to establish the mode of
action (MOA) in animals?
2. Are key events in the animal MOA plausible in humans?
3. Taking into account kinetic and dynamic factors, is the
animal MOA plausible in humans?
4. Conclusion: Statement of confidence, analysis, and
implications.
Site concordance between animals and humans is a funda-
mental initial premise on which mode of action frameworks are
based. As a result, in applying this framework for a given
chemical, tumors of each animal target organ observed are
evaluated independently, with the assumption that different
modes of action are possible in different organs, though based
on this analysis, modes of action in different tissues may be
similar. Similarly, an evaluation of the likelihood of congru-
ence between target organ(s) in different species and in humans
needs to be made, based on the mode of action analysis.
Is the Weight of Evidence Sufficient to Establish the Mode of
Action in Animals?
For each tumor type identified in an animal bioassay, the
current EPA and IPCS guidance frameworks (Sonich-Mullin,
et al., 2001; U.S. EPA, 1999) delineate specific topics for
organizing and presenting the information. The approach is
based on the Hill criteria for causality, originally developed for
application in epidemiologic investigations (Hill, 1965). IPCS
emphasized that its framework “is not a checklist of criteria,
but rather presents an analytical approach to considering the
weight-of-evidence of an MOA.”
The process of evaluating a mode of action in animals is
based on an explicitly stated proposed mode of action and
enumeration of key events. As defined by IPCS and EPA, key
events are measurable parameters associated with critical steps
in the mode of action. These steps and the framework for
evaluating an animal MOA are as follows: postulated MOA;
key events; associated critical parameters; dose-response rela-
tionships; temporal association; strength, consistency, and
specificity of association of key events and tumor response;
biological plausibility and coherence; possible alternative
MOAs; conclusion about the MOA; uncertainties, inconsisten-
cies, and data gaps.
This process incorporates an evaluation of the weight of
evidence for possible alternative MOAs at a given site and an
evaluation of the overall strength of evidence supporting the
MOA under consideration. Ultimately, a decision concerning
the weight of evidence supporting the MOA and the level of
confidence in that decision must be made. It also identifies
critically important data gaps that would increase confidence in
potential modes of action.
For a given chemical, the primary sources of information for
evaluating an MOA in animals often likely are data generated
for that specific chemical in the animal model. Obviously, data
from other sources can and should also be used, as appropriate,
along with data on chemicals with similar chemical structures,
similar modes of action, or both. If the mode of action for a
chemical is novel, considerably more data will be required to
support the conclusion that it is related to the carcinogenic
process of the tumors induced by that chemical than subse-
quent examples of chemicals acting by the same mode of
action. The working group did not address the issue of how
much data is sufficient to support a specific mode of action for
a given chemical, except by way of example within the case
studies. Consideration at this stage of the mode of action in the
context of potential variations between animals and humans
also facilitates addressing subsequent steps in the framework.
Are Key Events in the Animal MOA Plausible in Humans?
This represents a qualitative assessment of the relevance of
the MOA to human cancer potential. Listing the critical spe-
cific key events that occur in the animal mode of action and
directly evaluating whether each of the key events might or
might not occur in humans facilitated consideration and trans-
parent presentation of the relevant information. Presentation in
tabular form (as shown in Table 1 for atrazine), referred to as
a concordance table, can be helpful in delineating the relevant
information. The key events (and possibly some of the critical
associated processes) are listed with the information regarding
these events for the animal in which the tumor was observed.
It is intended that the information in these tables be brief, since
a narrative explanation is expected to accompany the table. In
the right-hand column, the effect in humans for each of the key
events is evaluated. An additional column for the results in a
different strain, species, or route of administration that does not
result in tumors can be useful if information is available for
comparison to the model that leads to tumors.
The evaluation of the concordance for a given chemical in
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humans is an evaluation of the MOA in humans, rather than an
evaluation of the specific chemical. What kinds of information
can be utilized to evaluate the key events in humans? Essen-
tially, such data can come from in vitro and in vivo studies on
the substance itself, but also can involve basic information
regarding anatomy, physiology, genetic disorders, epidemiol-
ogy, and any other information that is known regarding the key
events in humans. Information concerning an evaluation of the
key event in humans exposed directly to the chemical is fre-
quently unavailable.
In evaluating the concordance of the information in humans
to that in animals, a narrative describing the weight of evidence
and an evaluation of the level of confidence for the human
information needs to be provided. Some specific types of
information that are useful include the following: cancer inci-
dences at the anatomical site and cell type of interest, including
age, sex, ethnic differences and risk factors, including chemi-
cals and other environmental agents; knowledge of the nature
and function of the target site, including development, structure
(gross and histologic), and control mechanisms at the physio-
logical, cellular, and biochemical levels; human and animal
disease states that provide insight concerning target organ
regulation and responsiveness; human and animal responses to
the chemical under review or analogs following short, inter-
mediate, or long-term exposure, including target organs and
effects.
Obviously, a substantial amount of information is required
to conclude that the given mode of action is not relevant to
humans. If such a conclusion is strongly supported by the data,
then chemicals producing animal tumors only by that mode of
action would not pose a cancer hazard to humans, and no
additional risk assessment is required. Since there is no cancer
hazard, there is no cancer risk for the tumor under consider-
ation.
Taking Into Account Kinetic and Dynamic Factors, Is the
Animal MOA Plausible in Humans?
Toxicokinetic and toxicodynamic data are customary and
valuable contributions to the overall risk assessment process.
For purposes of human relevance analysis, if the animal MOA
is judged to be qualitatively relevant to humans, a more quan-
titative assessment is required, taking into account any toxico-
kinetic and toxicodynamic information that is available in both
the animal and in humans. Such data will, of necessity, be both
chemical and mode of action specific, requiring information
regarding the chemical and the mode of action in animals and
humans for comparison. Toxicokinetic considerations include
nature and time course of chemical uptake, distribution, me-
tabolism, and excretion, whereas toxicodynamic consider-
ations include the consequences of the interaction of the chem-
ical with cells. Of course, consideration of physiological,
cellular, and biochemical differences between species regard-
ing endogenous chemicals and control systems may be re-
quired.
Like the qualitative assessment, a tabular comparison be-
tween the animal and humans regarding quantitative issues can
be helpful. Similarly, the data for the quantitative assessment in
humans may not directly involve exposure to the chemical
under consideration, but may incorporate a more general eval-
uation in humans, involving information on the key events and
biologic processes that are known in general, rather than lim-
ited specifically to the chemical being evaluated. However, this
is the quantitative comparison, so it is a bit more of a stretch to
use “other data”—more so than for qualitative modes of action.
Statement of Confidence, Analysis, and Implications
Following the overall assessment of each of the three ques-
tions of the human relevance framework, a statement of con-
fidence is necessary that addresses the quality and quantity of
data underlying the analysis, consistency of the analysis within
the framework, consistency of the database, and the nature and
extent of the concordance analysis. An evaluation of alterna-
tive modes of action, using comparable analyses and rigor, is
also essential. A critically important outcome of adequate
consideration of the weight of the evidence for an overall mode
of action and the qualitative and quantitative concordance is
the identification of specific data gaps that can be addressed
experimentally in future investigations to increase confidence.
APPLICATION OF THE FRAMEWORK:
SOME EXAMPLES
An overall general schematic of the human relevance frame-
work and its relationship to risk assessment is shown in Figure
1. It is essential that, even if a specific mode of action cannot
be identified for a given chemical or if the mode of action is
qualitatively and quantitatively applicable to humans, the spe-
cific information evaluated during this analysis should be in-
corporated into the remaining steps of the risk assessment. In
many instances, critical pieces of information needed for eval-
uation of human risk will have been identified in this frame-
work analysis.
The modes of actions and chemicals that were evaluated by
TABLE 1
Concordance of Key Events in Rats and Humans: Atrazine
Key event
Evidence in animals
(rats)
Evidence in
humansSprague-Dawley F-344
Decreased GnRH pulses Yes No Unknown/possible
Suppression of LH surge Yes No Unknown/possible
Change in cyclicity Yes No No/not relevant
Prolonged increase in
estrogen/prolactin Yes No No
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the working group included direct or indirect genotoxicity
(acrylonitrile), interaction with proteins (d-limonene), and sup-
pression of luteinizing hormone (atrazine), increased hepatic
clearance of thyroxin (phenobarbital), sustained cytotoxicity
and regeneration (chloroform), and urinary tract calculi (mel-
amine). In addition, ethylene oxide was evaluated as an exam-
ple of a DNA-reactive carcinogen.
Two modes of action have been postulated for the carcino-
genicity of acrylonitrile in animal models, particularly related
to brain tumors: either direct DNA-reactivity of acrylonitrile
metabolites, or indirect DNA-reactivity by induction of oxida-
tive damage. It was concluded by our working group that the
data were insufficient to describe definitively the mode(s) of
action regarding acrylonitrile, so the answer to question 1, “Is
the weight of evidence sufficient to establish the mode of
action in animals?” was “no.” The consequence of this decision
is that the default assumption that the mode of action in the
animal bioassay is relevant to humans applies.
In contrast, the modes of action of the other chemicals used
for case studies have been well delineated. d-Limonene pro-
duces kidney tumors in male rats, but not in female rats or
either sex of mice. This has been attributed to the binding of
the epoxide of d-limonene to 2u-globulin, which is absorbed
into the proximal tubule but not digested, leading to toxicity of
the tubular cells and consequent cellular regeneration and
ultimately tumor formation. Although humans can metabolize
d-limonene to its epoxide, there is no functionally similar
protein in humans to which the epoxide can bind. Thus, one of
the critical events in the process, binding to 2u-globulin or a
similar protein, is precluded. Therefore, it can be concluded
that this MOA does not occur in humans. As a consequence,
while the answer to the question 1 was “yes,” the answer to
question 2, “Are key events in the animal mode of action
plausible in humans?” is “no.” Since the conclusion is that
there is no potential cancer hazard to humans, it can also be
concluded that there is no renal cancer risk.
Atrazine produces mammary tumors in female Sprague-
Dawley rats but not in F344 rats. A concordance table on
qualitative aspects of the key events for mammary tumors
produced by atrazine, with columns for both Sprague-Dawley
and F344 female rats, and a column for humans, is instructive
(Table 1). The specific information that distinguishes the F344
from the Sprague-Dawley rat can be used in evaluating similar
processes in humans. In Sprague-Dawley rats, atrazine affects
the hypothalamus, leading to inhibition of the LH surge during
the estrous cycle. This results in persistent secretion of estro-
gen and prolactin, ultimately leading to mammary tumors.
These hormonal changes do not occur in F344 female rats or in
CD-1 mice, a species that also is resistant to the mammary
carcinogenic activity of atrazine Even if the human hypothal-
FIG. 1. General schematic of the
human relevance framework and its rela-
tionship to risk assessment. The case-by-
case analyses are detailed and individu-
ally authored in Meek, et al. (2003). As
explained there, chemicals with gener-
ally well-established modes of action
were selected solely to develop and test
the framework. Case study authors relied
on the published literature, but did not
undertake the kind of comprehensive
mode of action review and summary de-
scribed for the PPAR agonists studied
in Klaunig et al. (2003).
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amus were affected by atrazine in a manner similar to the
Sprague-Dawley rat, a totally different result, mainly, a hy-
poestrogenic state, would be expected. Thus, it can be con-
cluded that the MOA for atrazine-induced mammary tumors in
Sprague-Dawley rats does not apply to humans, and, like
d-limonene, there is neither cancer hazard nor risk to humans
for this tumor.
Phenobarbital-induced thyroid tumors in rats pose a different
set of circumstances. (Note: To fully evaluate phenobarbital
would have required separately addressing the mode of action
of liver tumors.) Phenobarbital induces liver enzymes involved
in the metabolism of thyroid hormones, leading to decreased
levels in the blood. Reduced thyroid hormone results in stim-
ulation of the pituitary to produce more TSH, which induces
the thyroid to attempt to produce thyroid hormone to replace
the amount being metabolized and to enhance follicular cell
proliferation, eventually leading to follicular cell hyperplasia,
adenomas, and carcinomas. This same liver metabolizing pro-
cess and pituitary-thyroid axis is present in humans, so on a
qualitative basis, there is the potential that this mode of action
could be operative in humans. However, because of differences
in the pharmacokinetics of thyroid hormones between rats and
humans, doses of phenobarbital in humans, although inducing
the enzymes leading to the metabolism of thyroid hormones,
do not result in a sufficiently decreased level of thyroid hor-
mones to produce a TSH increase. Neither phenobarbital nor
other liver enzyme inducers have been shown to increase TSH
or to lead to changes in follicular cells in humans. Also,
increases in TSH in humans due to other mechanisms fre-
quently lead to an increase in thyroid follicular colloid forma-
tion and follicular hypertrophy rather than follicular cell pro-
liferation and hyperplasia. Thus, on both quantitative kinetic
and dynamic bases, the response in rats does not occur in
humans, even though on a qualitative basis the human has the
potential. One can thus conclude on a quantitative basis that
this MOA does not apply to humans, and like d-limonene and
atrazine, neither a carcinogenic hazard nor risk to humans is
likely.
The remaining three chemicals, ethylene oxide, chloroform
and melamine, all have modes of action that are qualitatively
and quantitatively possible in humans, thus indicating the
relevance of their modes of action to humans. However, al-
though all three chemicals result in the same answers to the
three questions we are posing, the implications for risk assess-
ment are quite different.
For ethylene oxide, the MOA is believed to be based on
DNA reactivity, the formation of DNA adducts, leading to
DNA mutation and an increased risk of cancer. Obviously, this
is possible in both animals and in humans, both qualitatively
and quantitatively. Although there may be differences in the
quantitative levels in animals versus humans, nevertheless, the
process is possible in humans. Thus, a full risk assessment
taking this into account in humans is essential. Differences in
toxicokinetics between animals and humans can be best taken
into account utilizing validated physiologically based pharma-
cokinetic (PBPK) models.
Chloroform produces kidney and liver tumors in rodents,
and the MOA is similar in both tissues, involving oxidative
metabolism of chloroform, leading to cytotoxicity and regen-
erative proliferation. Regenerative proliferation goes on to
liver or kidney tumor formation in rodents. This sequence of
events of metabolism and cytotoxicity occurs both in rodents
and in humans. However, the sequence of events involves a
process producing cytotoxicity that is considered to reflect a
nonlinear response. Without cytotoxicity, tumors are not ex-
pected to develop. Taking into account differences in the
kinetics with a PBPK model, one can reasonably project the
levels required to produce toxicity in humans and to estimate
levels that might be required to produce tumors. Thus, the
approach to risk assessment for chloroform would vary from
that for a DNA-reactive carcinogen such as ethylene oxide.
Melamine offers still a different kind of example. Melamine
administered at sufficiently high doses produces lower urinary
tract calculi in rats, which produce urothelial damage, conse-
quent regeneration, and bladder tumor formation. This is
clearly a threshold phenomenon, requiring a dose of melamine
sufficient to produce calculi. A similar sequence of events is
possible in humans, although the response to calculi is quan-
titatively significantly less in humans with respect to carcino-
genic risk, compared to rodents, especially rats. While little is
known regarding the actual chemical exposure in humans,
there is considerable information available regarding the for-
mation of calculi in the human urinary tract and the resulting
response of the urothelium. Based on both qualitative and
quantitative assessments, this MOA is possible in humans.
Although melamine can be considered to pose a potential
cancer hazard to humans in principle, actual risk is dependent
entirely on level of exposure. It has been estimated that the
exposure to melamine at currently estimated levels may be 4–5
orders of magnitude lower than that which would be required
to produce calculi. If that is the case, melamine does not pose
a carcinogenic risk to humans. This distinction is important,
and clarity in the distinction of mode of action in hazard
characterization, separate from exposure analysis and risk as-
sessment, is a critically important contribution of the frame-
work to increasing transparency and common understanding.
During the course of this project, a second ILSI RSI working
group examined current data and analyses on the modes of
action of a subclass of peroxisome proliferating chemicals,
with a focus on characterizing the animal MOAs for peroxi-
some proliferator-activated receptor  (PPAR)-agonists in
liver, pancreatic acinar cell, and Leydig cell tumors. As re-
ported in a companion paper (Klaunig et al., 2003), that group
successfully applied the new human relevance framework to
chemicals operating through the PPAR mode of action. For
pancreatic acinar cell and testicular Leydig cell tumors in rats,
the MOA was considered to not be sufficiently delineated yet,
so the answer to question 1 is “no”. In contrast, the MOA for
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rodent liver tumors was considered to be adequately defined.
Based on a variety of investigations, it was also concluded that,
based strictly on qualitative considerations, the MOA was
relevant to humans. However, based on quantitative toxicody-
namic data, it was concluded that the answer to question 3 is
“no,” that it is not relevant to humans, similar to the conclusion
regarding phenobarbital-induced thyroid tumors.
SUMMARY
Current EPA and IPCS guidance offers excellent starting
points for animal tumor MOA analysis. To complement and
supplement this existing guidance, additional elements of a
framework analysis have been developed, on the basis of case
studies, to transparently evaluate the relevance of the animal
MOA to humans. This led primarily to the establishment of
concordance analyses between the species producing tumors
and humans. The expanded framework takes into account both
qualitative and quantitative aspects of the MOA, addresses the
issue of the kinds of data that can be used in evaluating the
MOA in humans, and provides a disciplined, transparent ap-
proach to comparing the key events of the MOA in laboratory
animals to humans. It also identifies critical data gaps in
assessing relevance to humans of postulated modes of action.
Although not addressed specifically by the present working
group, it became apparent that other end points of toxicity (e.g.,
manifestations of reproductive, developmental, or neurotoxic-
ity) might be addressed by this framework in similar fashion,
because several of the modes of action examined in the first
exercise involved intermediate, noncancer events. Another
working group has been formed to address this hypothesis.
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